Charnell Cain
Family Medicine · Houston, TXNPI 1265812630
Payments from drug & device makers
Across 123 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$421
- Novo Nordisk$360
- AstraZeneca$221
- Amgen$158
- Teva Pharmaceuticals USA, Inc.$133
- Lilly USA, LLC$93
- plus $558 from 12 others
What the payments were for
- Food & beverage$1,90498%
- Education$402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 25 | $421 |
| Novo Nordisk | 27 | $360 |
| AstraZeneca | 9 | $221 |
| Amgen | 10 | $158 |
| Teva Pharmaceuticals USA, Inc. | 9 | $133 |
| Lilly USA, LLC | 7 | $93 |
| Pfizer | 6 | $87 |
| Merck | 5 | $82 |
| Exact Sciences | 4 | $72 |
| GSK | 5 | $68 |
| Sanofi-aventis U.S. LLC | 4 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| Boehringer Ingelheim | 3 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Phadia US Inc. | 1 | $22 |
| Masimo Corporation | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$1,944 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 23 | $29,923 |
| OzempicSemaglutide | 18 | $17,353 |
| EliquisApixaban | 12 | $15,766 |
| TrulicityDulaglutide | 12 | $15,557 |
| GlyxambiEmpagliflozin/Linagliptin | 13 | $14,864 |
| JanuviaSitagliptin Phosphate | 11 | $5,617 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $5,448 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $3,363 |
| Esomeprazole Magnesium | 16 | $1,934 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,406 |
| Atorvastatin Calcium | 167 | $1,265 |
| Amlodipine Besylate | 193 | $918 |
| Gabapentin | 60 | $719 |
| Ventolin HfaAlbuterol Sulfate | 13 | $685 |
| Rosuvastatin Calcium | 21 | $602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi | $37 | $44,78736 claims |
| Novo NordiskOzempic | $360 | $17,35318 claims |
| PfizerEliquis | $87 | $15,76612 claims |
| Lilly USA, LLCTrulicity | $93 | $15,55712 claims |
| MerckJanuvia | $82 | $5,61711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Houston
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
- Bonnie ColvilleHouston$19.6M
- Oscar de ValleHouston$12.8M
- van TranHouston$11M
- Joe PouzarHouston$10.7M
- Aalia Al-BarwaniHouston$6.8M
- Terence ChangHouston$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.